CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

Scientists at UC San Francisco have discovered how pancreatic cancer cells thrive in the lungs or liver, environments that ...

Dr. Bryant Lin, who has stage 4 lung cancer, created a Stanford class that follows his journey, offering students an ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

Inflammation fuels the high rate of cancer in people over 50, researchers find, leading them to test anti-inflammatories like ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence ...